Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases

Sexually Transmitted Diseases

Volumn 34, Issue 7, 2007, Pages 503-507

  Dempsey, Amanda F ^a,c   Koutsky, Laura A ^b   Golden, Matthew ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHLAMYDIASIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEALTH CARE UTILIZATION; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SCHOOL CHILD; SEXUALLY TRANSMITTED DISEASE; URETHRITIS; VACCINATION; VERRUCA VULGARIS; WORKLOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RETROSPECTIVE STUDIES; SEXUALLY TRANSMITTED DISEASES; WASHINGTON; WORKLOAD;

EID: 34250843134     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000253337.62932.29     Document Type: Article

References (12)

1. U.S. Food and Drug Administration. Product Approval Information-Licensing Action. Gardasil. 2006.
2. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004; 364:1757-1765.
3. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of human papillomavirus type 16 vaccine. NEJM 2002; 347:1645-1651.
4. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-278.
5. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993; 20:274-278.
6. Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis 1993; 20:286-289.
7. Hildesheim A, Gravitt P, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-income women in Washington, D.C. Sex Transm Dis 1993; 20:279-285.
8. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218-226.
9. Burk RD, Ho GY, Beardsley L, et al. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996; 174: 679-689.
10. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001; 183:1554-1564.
11. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-428.
12. STD Facts: Human Papillomavirus. 2004. Available at http://www.cdc.gov/ std/HPV/STDFact-HPV.htm. Accessed May 10, 2006.